Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • Log out
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology

Epidemiologic Evaluation of Antimicrobial Resistance in Community-Acquired Enterococci

J. Silverman, L. A. Thal, M. B. Perri, G. Bostic, M. J. Zervos
J. Silverman
Departments of Medicine and Clinical Pathology, William Beaumont Hospital, Royal Oak, 1 and Wayne State University, Detroit, 2 Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. A. Thal
Departments of Medicine and Clinical Pathology, William Beaumont Hospital, Royal Oak, 1 and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. B. Perri
Departments of Medicine and Clinical Pathology, William Beaumont Hospital, Royal Oak, 1 and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Bostic
Departments of Medicine and Clinical Pathology, William Beaumont Hospital, Royal Oak, 1 and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. J. Zervos
Departments of Medicine and Clinical Pathology, William Beaumont Hospital, Royal Oak, 1 and Wayne State University, Detroit, 2 Michigan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Fecal samples from 200 consecutive patients admitted to a community hospital yielded 107 enterococci. High-level gentamicin resistance occurred in 10 (14%) of the Enterococcus faecalisisolates. Ampicillin resistance occurred in two (3%) of the E. faecalis isolates and six (23%) of the Enterococcus faecium isolates. There were no vancomycin-resistant enterococci. Risk factors for enterococci with high-level aminoglycoside (gentamicin) or ampicillin resistance included prior hospitalization and previous antibiotic use.

Enterococci are widely distributed in nature. The natural habitat of these organisms is the intestinal tracts of humans and animals. Enterococci are important causes of hospital-acquired infection (19, 24). They are the second most common cause of nosocomial infections and the third most common cause of nosocomial bacteremia (24). Within recent years, a great deal has been learned about the epidemiology of and risk factors for nosocomial enterococcal infection, with person-to-person spread of antibiotic-resistant isolates well documented (23, 28, 29).

Enterococci are also important causes of community-acquired infection (15, 19). These enterococcal infections have been traditionally thought of as endogenous and arising from the patient’s own flora. Microorganisms from endogenous sources subsequently cause infection by invasion of commensal flora which infect because of some alteration in host defenses. The sources and reservoirs that play a role in the resistance to antibiotics of enterococci that are community acquired are not known. In earlier studies in the United States and Europe, community acquisitions of gentamicin-resistant enterococci (21) and of glycopeptide-resistant enterococci (VRE) (2, 3, 14, 27), respectively, were documented, suggesting a reservoir in the community. Little is currently known concerning the epidemiology or prevalence of resistant enterococci in the community setting. We therefore evaluated the prevalence and risk factors for fecal carriage of antibiotic-resistant enterococci in patients admitted to the hospital.

William Beaumont Hospital is a 925-bed community teaching hospital. We prospectively studied 200 consecutive patients admitted to the hospital over a 3-month period in 1993. All hospitalized patients gave written informed consent and were hospitalized on three 60-bed medical floors. Demographic and risk factor information and stool samples were collected within 48 h of admission. Fecal samples were grown on Columbia CNA agar (BBL, Cockeysville, Md.) and brain heart infusion agar (Difco Co., Detroit, Mich.). From each culture, three separate colony types were evaluated. Identification to the species level was performed by biochemical reactions as described by Facklam and Collins (10). In vitro susceptibilities of strains to gentamicin, streptomycin, ampicillin, and vancomycin were determined by use of a published standardized microdilution technique (13, 22). β-Lactamase production was determined by nitrocefin disks (Becton Dickinson, Cockeysville, Md.). High-level aminoglycoside resistance was defined by an MIC of >2,000 μg/ml.

Patient groups that were compared in the statistical analysis included hospitalized patients with Enterococcus faecalis andEnterococcus faecium and control patients from whose stool samples enterococci were not isolated. Hospitalized patients with antimicrobial-susceptible enterococci and patients with ampicillin- or aminoglycoside-resistant enterococci were also compared. The statistical significance between groups was evaluated by using tests of homogeneity of odds and the two-tailed Fisher’s exact test for bivariate analysis of dichotomous-outcome data. Continuous variables were compared with the Mann-Whitney U test. A multivariate logistic regression model was used to evaluate the independence of risk factors.

We monitored 200 patients with 200 admissions (94 men and 106 women). Of these patients, six had more than one enterococcal isolate. Hospitalized patients with Enterococcus spp. isolated ranged in age from 29 to 82 years (mean, 63 years); 100 (50%) of the patients were culture positive for Enterococcus spp. Of the enterococci cultured, 73 isolates (68%) were E. faecalis, 26 (24%) were E. faecium, 5 (4%) were Enterococcus gallinarum, and 3 (3%) were Enterococcus hirae.

Of the 73 E. faecalis isolates, 8 (11%) demonstrated high-level gentamicin plus high-level streptomycin resistance and 13 (18%) showed high-level streptomycin resistance in the absence of high-level gentamicin resistance. Of the 26 E. faeciumisolates, none (0%) showed high-level gentamicin plus high-level streptomycin resistance and 4 (15%) demonstrated high-level streptomycin resistance in the absence of high-level gentamicin resistance. The MIC of vancomycin for all isolates was <8.0 μg/ml, with the exception of one E. gallinarum isolate, for which the MIC was 8.0 μg/ml. The other four E. gallinarumisolates required MICs of vancomycin of 4.0 μg/ml. Of the isolates with high-level streptomycin resistance, 21 were E. faecaliswhile 4 were E. faecium. No β-lactamase-positive isolates were identified.

Risk factors and demographic characteristics for hospitalized patients and controls are summarized in Table 1. The mean age of patients with E. faecalis was 64 years (range, 20 to 80 years), the mean age of patients with E. faecium was 65 years (range, 20 to 80 years), and the mean age of controls was 61 years (range, 20 to 80 years). Prior hospitalization was most common in patients with E. faecalis. There were no significant differences in the risk factor variables specific forEnterococcus spp. studied.

View this table:
  • View inline
  • View popup
Table 1.

Risk factors for species of Enterococcusisolated from inpatients

A comparison of risk factors for patients with ampicillin-resistant enterococci, high-level-gentamicin-resistant enterococci, and ampicillin-susceptible plus gentamicin-susceptible enterococci is shown in Table 2. Prior hospitalization was significantly more common in patients with high-level-gentamicin-resistant and ampicillin-resistant enterococci than in controls (P < 0.001). Previous antibiotic use was significantly more common in patients with ampicillin-resistant enterococci than in controls (P = 0.03). None of the variables analyzed was significant in the multivariate analysis.

View this table:
  • View inline
  • View popup
Table 2.

Risk factors for antimicrobial resistance in hospitalized patients from whom enterococci were isolated

In the past decade, there has been a rapid rise in the number of serious nosocomial infections caused by enterococci resistant to multiple antibiotics. Enterococci with high-level gentamicin resistance were first identified in the 1980s, with intra- and interhospital spread seen in nursing homes and hospitals (23, 28, 29). Subsequently, ampicillin-resistant enterococci, including β-lactamase-producing and non-β-lactamase-producing strains, were isolated (4, 9, 12, 20). Most recently, glycopeptide-resistant strains among hospitals in separate states have become a major concern (5-7, 11, 18, 26).

To help determine the basis for the spread of antibiotic resistance in enterococci, we analyzed the prevalence of resistance in fecal samples, risk factors, and epidemiology in patients admitted to a large community teaching hospital in southeastern Michigan. For patients admitted to the hospital, we found that 50% of them had enterococci isolated from stool, with 68% of the isolates being E. faecalis and 24% of them being E. faecium. These findings show a lower level of fecal colonization with enterococci than that demonstrated by other surveys (15). Enterococci present in stool in small numbers or some strains exhibiting resistance may have been below the limits of detection by our methods. Since media specifically selective for VRE isolation were not used, some of these strains may have been missed. In the United States, VRE appear to have spread in hospitals. Community acquisition of strains has not been reported (8). Importantly, vancomycin-resistant enterococci were not cultured from the population we studied. In Europe, however, vancomycin-resistant strains have been isolated from asymptomatic outpatients and from animals, food, and sewage, showing various community reservoirs (1-3, 16, 17, 25); these findings indicate important differences in the epidemiology of VRE in Europe and the United States. These differences may be related to the use of avoparcin in animal feed in Europe and the overuse of vancomycin in hospitalized patients in the United States.

In this study, previous antibiotic administration and hospitalization within the past 3 months were significant variables associated with colonization by enterococci with ampicillin or high-level gentamicin resistance. The small numbers of patients with resistant organisms limited the statistical analysis. In patients without recent hospitalization, resistant strains were rare, suggesting nosocomial acquisition of strains during prior admissions. Increasing awareness of these resistant organisms as colonizing strains may lead to a change in control measures at sites where patients are known to be frequently readmitted, such as oncology or renal units; at such sites, periodic surveillance cultures and screening for resistance may be warranted.

ACKNOWLEDGMENTS

This work was supported in part by the William Beaumont Hospital Research Institute and by Public Health Service grant H50/CCH513220-01 from the Centers for Disease Control and Prevention.

We thank Rosalind Smith for assistance in the preparation of the manuscript.

FOOTNOTES

    • Received 12 June 1997.
    • Returned for modification 31 July 1997.
    • Accepted 2 December 1997.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. ↵
    1. Aarestrup F. M.,
    2. Ahrens P.,
    3. Madsen M.,
    4. Pallesen L. V.,
    5. Poulsen R. L.,
    6. Westh H.
    (1996) Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the vanA cluster. Antimicrob. Agents. Chemother. 40:1938–1940.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Bates J.,
    2. Jordens Z.,
    3. Griffiths D. T.
    (1994) Farm animals as a putative reservoir for vancomycin resistant enterococcal infection in man. J. Antimicrob. Chemother. 34:507–516.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Bates J.,
    2. Jordens Z.,
    3. Selkon J. B.
    (1993) Evidence for an animal origin of vancomycin resistant enterococci. Lancet 342:490–491.
    OpenUrlPubMedWeb of Science
  4. ↵
    1. Boyce J. M.,
    2. Opal S. M.,
    3. Patter-Bynoe G.,
    4. LaForge R. G.,
    5. Zervos M. J.,
    6. Furtado G.,
    7. Victor G.,
    8. Medeiros A. A.
    (1992) Emergence and nosocomial transmission of ampicillin-resistant enterococci. Antimicrob. Agents Chemother. 36:1032–1039.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Boyce J. M.,
    2. Opal S. M.,
    3. Chow J. W.,
    4. Zervos M. J.,
    5. Potter-Bynoe G.,
    6. Sherman C. B.,
    7. Romulo R. L. C.,
    8. Fortna S.,
    9. Medeiros A. A.
    (1994) Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J. Clin. Microbiol. 32:1148–1153.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Boyle J. F.,
    2. Soumakis S. A.,
    3. Rendo A.,
    4. Herrington J. A.,
    5. Gianarkis D. G.,
    6. Thurberg B. E.,
    7. Painter B. G.
    (1993) Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J. Clin. Microbiol. 31:1280–1285.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Chow J. W.,
    2. Kuritza A.,
    3. Schlaes D. M.,
    4. Green M.,
    5. Sahm D. F.,
    6. Zervos M. J.
    (1993) Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. J. Clin. Microbiol. 31:1609–1611.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Coque T. M.,
    2. Arduino R. C.,
    3. Murray B. E.
    (1995) High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci. Clin. Infect. Dis. 20:1048–1051.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Donabedian S. M.,
    2. Chow J. W.,
    3. Boyce J. M.,
    4. McCabe R. E.,
    5. Markowitz S. M.,
    6. Coudron P. E.,
    7. Kuritza A.,
    8. Pierson C. L.,
    9. Zervos M. J.
    (1992) Molecular typing of ampicillin-resistant, non-beta-lactamase-producing Enterococcus faecium isolates from diverse geographic areas. J. Clin. Microbiol. 30:2757–2761.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Facklam R. R.,
    2. Collins M. D.
    (1989) Identification of Enterococcus spp. isolated from human infections by a conventional test scheme. J. Clin. Microbiol. 27:731–734.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Frieden T. R.,
    2. Munsiff S. S.,
    3. Low D. E.,
    4. Willey B. M.,
    5. Williams G.,
    6. Faur Y.,
    7. Eisner W.,
    8. Warren S.,
    9. Kreiswirth B.
    (1993) Emergence of vancomycin resistant enterococci in New York City. Lancet 342:76–79.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Grayson M. L.,
    2. Eliopoulos G. M.,
    3. Wennerstein C. B.,
    4. Ruoff K. L.,
    5. DeGirolami P. C.,
    6. Ferrara M.,
    7. Moellering R. C. Jr.
    (1991) Increasing resistance to β-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob. Agents Chemother. 35:2180–2184.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Jones R. W.,
    2. Barry A. L.,
    3. Gavan T. L.,
    4. Washington J. A. II.
    (1985) Susceptibility tests: microdilution and macrodilution broth procedures. in Manual of clinical microbiology, eds Lennette E. H., Balows A., Hausler W. J., Shadomy H. J. (American Society for Microbiology, Washington, D.C), 4th ed. pp 972–977.
  14. ↵
    1. Jordens J. Z.,
    2. Bates J.,
    3. Griffiths D. T.
    (1994) Faecal carriage and nosocomial spread of vancomycin resistant Enterococcus faecium. J. Antimicrob. Chemother. 34:515–528.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Kaye D.
    (1982) Enterococci: biologic and epidemiologic characteristics and in vitro susceptibility. Arch. Intern. Med. 142:2006–2009.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Klare, L., H. Heier, H. Claus, R. Reissbrodt, and W. Witte. VanA-mediated high-level glycopeptide resistance inEnterococcus faecium from animal husbandry. FEMS Microbiol. Lett., in press.
  17. ↵
    1. Klare L.,
    2. Heier H.,
    3. Claus H.,
    4. Witte W.
    (1993) Environmental strains of Enterococcus faecium with inducible high-level resistance to glycopeptides. FEMS Microbiol. Lett. 106:23–30.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Leclercq R.,
    2. Derlot E.,
    3. Duval J.,
    4. Courvalin P.
    (1988) Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319:157–161.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Murray B. E.
    (1990) The life and times of the enterococcus. Clin. Microbiol. Rev. 3:46–65.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Murray B. E.,
    2. Singh K. V.,
    3. Markowitz S. M.,
    4. Lopardo H. A.,
    5. Pattersen J. E.,
    6. Zervos M. J.,
    7. Rubeglio E.,
    8. Eliopoulos G. M.,
    9. Rice L. B.,
    10. Goldstein F. W.,
    11. Jenkins S. G.,
    12. Caputo G. M.,
    13. Nasnas R.,
    14. Moore L. S.,
    15. Wong E. S.,
    16. Weinstock G.
    (1991) Evidence for clonal spread of a single strain of β-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J. Infect. Dis. 163:780–785.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Nachamkin E.,
    2. Axelrod P.,
    3. Talbot G. H.,
    4. Fascher S. H.,
    5. Wennersten C. B.,
    6. Moellering R. C. Jr.,
    7. MacGregor R. R.
    (1988) Multiply high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital. J. Clin. Microbiol. 26:1287–1291.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. National Committee for Clinical Laboratory Standards
    (1990) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved standard M7-A2. (National Committee for Clinical Laboratory Standards, Villanova, Pa).
  23. ↵
    1. Patterson J. E.,
    2. Zervos M. J.
    (1990) High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology. Rev. Infect. Dis. 12:644–652.
    OpenUrlPubMedWeb of Science
  24. ↵
    1. Schaberg D. R.,
    2. Culver D. H.,
    3. Gaynes R. P.
    (1991) Major trends in the etiology of nosocomial infections. Am. J. Med. 91:725–755.
    OpenUrl
  25. ↵
    1. Thal L. A.,
    2. Chow J. W.,
    3. Mahayni R.,
    4. Bonilla H.,
    5. Perri M. B.,
    6. Donabedian S. A.,
    7. Silverman J.,
    8. Taber S.,
    9. Zervos M. J.
    (1995) Characterization of antimicrobial resistance in enterococci of animal origin. Antimicrob. Agents Chemother. 39:2112–2115.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Uttley A. H. C.,
    2. Collins C. H.,
    3. Naidoo J.,
    4. George R. C.
    (1988) Vancomycin resistant enterococci. Lancet i:57–58.
    OpenUrlCrossRef
  27. ↵
    1. Van der Auwera P.,
    2. Pensart N.,
    3. Korten V.,
    4. Murray B. E.,
    5. Leclercq R.
    (1996) Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide resistant enterococci. J. Infect. Dis. 173:1129–1136.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Zervos M. J.,
    2. Dembinski S.,
    3. Mikesell T.,
    4. Schaberg D. R.
    (1986) High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition of infection. J. Infect. Dis. 153:1075–1083.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Zervos M. J.,
    2. Terpenning M. S.,
    3. Schaberg D. R.,
    4. Therasse P. M.,
    5. Medendorp S. V.,
    6. Kauffman C. A.
    (1987) High-level aminoglycoside resistant enterococci: colonization of nursing home and acute care hospital patients. Arch. Intern. Med. 147:1591–1594.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Epidemiologic Evaluation of Antimicrobial Resistance in Community-Acquired Enterococci
J. Silverman, L. A. Thal, M. B. Perri, G. Bostic, M. J. Zervos
Journal of Clinical Microbiology Mar 1998, 36 (3) 830-832; DOI:

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Epidemiologic Evaluation of Antimicrobial Resistance in Community-Acquired Enterococci
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
Share
Epidemiologic Evaluation of Antimicrobial Resistance in Community-Acquired Enterococci
J. Silverman, L. A. Thal, M. B. Perri, G. Bostic, M. J. Zervos
Journal of Clinical Microbiology Mar 1998, 36 (3) 830-832; DOI:
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X